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Probucol suppresses ICAM-1 expression in rat mesangial cells: effects. However, little is known about the mechanism
Possible role of IL-1. Interleukin-1 (IL-1) participates in the of probucol’s action on glomerular injury.
progression of glomerulonephritis by up-regulating intercellu- In the present brief report, we focus on the action of
lar adhesion molecule-1 (ICAM-1) expression in experimental
probucol on interleukin-1 (IL-1) secretion and discussglomerulonephritis. Probucol, an anti-hyperlipidemic agent,
the possible mechanism by which probucol may suppressameliorates some types of glomerulonephritis regardless of
serum cholesterol levels, and is also reported to inhibit IL-1 glomerular injury.
release from macrophages in atherosclerotic lesions. However,
little is known about the mechanism of this favorable action
on glomerular injury. We examined whether or not probucol ROLE OF INTERLEUKIN-1 IN
inhibits ICAM-1 expression by suppression of IL-1 action in GLOMERULONEPHRITIS
cultured rat mesangial cells. In this brief report, we review the
Recent studies have shown that many cytokines,actions of probucol on IL-1 secretion and discuss the possible
growth factors and vasoactive substances participate inmechanism by which probucol may suppress the glomerular
injury. the development of glomerular lesions in experimental
and human glomerulonephritis. Among these cytokines,
IL-1 has been known to contribute to the early stage of
inflammation in glomerulonephritis. IL-1 has two typesA number of studies have demonstrated the beneficial
of actions on mesangial cells (Fig. 1). One importanteffects of anti-hyperlipidemic therapy on the progression
action is to promote cell proliferation. Although IL-1of renal injury. Inhibition of 3-hydroxy-3-methylglutaryl
alone does not promote mesangial cell proliferation, itco-enzyme A (HMG-CoA) reductase, a lipid-lowering
synergistically increases proliferation induced by plate-agent reported to exhibit the greatest reduction in low
let-derived growth factor (PDGF) or basic fibroblastdensity lipoprotein (LDL) in nephrotic syndrome, ame-
growth factor (bFGF) in mesangial cells. We have dem-liorates proteinuria and glomerulosclerosis in various ex-
onstrated that this synergistic action of IL-1 is mediatedperimental models [1–5]. Probucol, an anti-hyperlipid-
through secretion of group II phospholipase A2 (PLA2)emic agent originally developed as an antioxidant, also
[3]. The other important action of IL-1 is to provokeattenuates proteinuria and glomerulosclerosis in puro-
leukocyte infiltration, which is mediated, at least inmycin aminonucleoside nephritis (PAN) rats. Recent
part, by up-regulating intercellular adhesion molecule-1studies have shown that probucol reduced the extent of
(ICAM-1) expression on mesangial cells.renal injury, as evidenced by proteinuria and glomerular
The interaction between ICAM-1, a member of immu-lesions, in cholesterol-fed ExHC rats and in passive Hey-
noglobulin superfamily expressed on a variety of cellsmann nephritis [reviewed in 6]. Probucol ameliorates the
including mesangial cells, and its counter receptor (lym-renal injury in the absence of significant reduction in
phocyte function-associated antigen-1; LFA-1) play aplasma cholesterol levels in these models, suggesting that
key role in glomerular leukocyte infiltration in experi-the effect produced is not simply due to its hypolipidemic
mental models. IL-1 is reported to induce ICAM-1 ex-
pression in many types of cells in vitro. Northern blot
analysis of ICAM-1 mRNA showed that exogenous IL-1Key words: glomerulonephritis, intercellular adhesion molecule-1, in-
terleukin-1, progressive renal disease. rapidly up-regulated ICAM-1 mRNA expression, with
its peak at four to six hours after stimulation in cultured 1999 by the International Society of Nephrology
S-167
Sugiura et al: Probucol suppresses ICAM-1 in mesangial cellsS-168
Fig. 1. Schematic of interleukin-1 (IL-1) action on mesangial cells. IL-1
from infiltrating macrophages (Mφ) acts on mesangial cells (MC). IL-1
also acts in an autocrine or paracrine manner. One important action
of IL-1 is to promote cell proliferation. IL-1 synergistically increases
proliferation induced by PDGF or bFGF through the action of secreted
group II PLA2. The other important role is to provoke leukocyte infil-
tration by increasing ICAM-1 expression. Probucol may inhibit ICAM-1
expression by suppression of IL-1 in an autocrine fashion.
rat mesangial cells (Fig. 2A). Indeed, IL-1-provoked leu-
kocyte adhesion on cultured mesangial cells was inhib-
ited by anti-ICAM-1 antibody [4].
In rat antiglomerular basement membrane (GBM)
glomerulonephritis, treatment with IL-1 receptor antag-
onist (IL-1ra) has been shown to reduce glomerular in-
jury and leukocyte infiltration [5, 6]. This suppression of
tissue injury proved to be associated with the reduction
of ICAM-1 expression, suggesting that IL-1 participated
Fig. 2. Northern blot analysis of intercellular adhesion molecule-1in the pathogenesis of glomerulonephritis by up-regulat-
(ICAM-1) mRNA expression. (A) Total RNA was isolated from rating ICAM-1 expression in this model [7]. Of note, the mesangial cells treated with 200 U/ml IL-1b. Northern blot analysis, in
expression of ICAM-1 has been observed in mesangial which 20 mg of total RNA was applied in each line, was performed
using 32P-labeled ICAM-1 cDNA. EtBr is ethidium bromide stainingcells in this model, which suggests the involvement of
of ribosomal RNA. (B) Total RNA was isolated from rat mesangial cellsmesangial cells in the early phase of inflammatory reac- treated with 10 mg/ml lipopolysaccharide (LPS) either in the presence or
tions in this model. Considering these data, it may be absence of 10 mg/ml probucol at six hours after stimulation. Northern
blot analysis was performed using 32P-labeled ICAM-1 cDNA. Thebeneficial to inhibit autocrine IL-1 secretion from mesan-
radioactivity of the hybridized probe was measured with a computing
gial cells so as to reduce this aspect of the inflammatory densitometer. Abbreviations are: C, control; L, 10 mg/ml LPS; L 1 P,
10 mg/ml LPS with 10 mg/ml probucol. Results are mean 6 se of threeprocesses in glomerulonephritis.
experiments. *P , 0.05 vs. control. (C) Rat mesangial cells were treated
as in Fig. 2B, and culture medium was collected at six hours after
stimulation. IL-1 activity was measured by lectin-primed thymocytePROBUCOL INHIBITS ICAM-1 EXPRESSION ON
proliferation assay. Results are mean 6 se of four experiments. *P ,
MESANGIAL CELLS 0.05 vs. control; **P , 0.05 vs. LPS stimulation. (Fig. 2 B and C were
reproduced from [2] with permission from Nephrology).We have recently reported that probucol inhibits
ICAM-1 mRNA and ICAM-1 protein expression by sup-
pression of IL-1 activity in cultured rat mesangial cells [2].
Lipopolysaccharide (LPS), a strong stimulant to release
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IL-1 from mesangial cells, was shown to induce ICAM-1 that LPS and probucol might regulate IL-1 activity at the
mRNA expression on mesangial cells (Fig. 2B). Quies- post-translational level in mesangial cells [2]. In addition,
cent mesangial cells were incubated with LPS either in IL-1b processing and secretion is stringent and complex.
the presence or absence of probucol for 24 hours. LPS IL-1b is synthesized as a 31 to 34 kDa precursor (proIL-
increased ICAM-1 mRNA expression by fivefold and 1b) and is processed to mature 17 kDa biologically active
probucol notably reduced this induction. In addition, form by IL-1b-converting enzyme (ICE) [9]. Probucol
IL-1 receptor antagonist (IL-1ra) suppressed LPS-induced may affect the processing of IL-1 activation. Interest-
ICAM-1 mRNA expression on mesangial cells in a dose- ingly, nitric oxide (NO) was shown to increase IL-1 activ-
dependent manner and 100 ng/ml IL-1ra completely in- ity in murine macrophages. NO increases the IL-1 activ-
hibited ICAM-1 expression, indicating that the induction ity as well as the amount of IL-1 protein as determined
was elicited through the action of secreted IL-1 in an enzyme-linked immunosorbent assay, not by an alter-
autocrine manner [2]. It is interesting that the changes ation of IL-1 expression nor by modification of IL-1
of ICAM-1 observed at mRNA levels were also con- precursor processing, but by a cyclic GMP-dependent
firmed at protein levels within 24 hours after stimulation mechanism [10]. Therefore, LPS may increase IL-1 activ-
by immunoblotting. ity through the actions of NO, which is a reactive free
Probucol has been known to reduce the progression radical, and probucol, an antioxidant, may inhibit the
of atherosclerotic lesions. Atherosclerotic lesion results release of IL-1 activity by blocking NO. Further studies
from the accumulation of foam cells of monocyte/macro- are necessary to clarify the mechanism responsible for
phage origin within the arterial intima. IL-1 from these the regulation of IL-1 activity.
cells plays an important role in the formation of athero-
sclerotic lesion. Since probucol is reported to inhibit IL-1
CONCLUSIONrelease from macrophages, probucol may ameliorate ath-
Interleukin-1 and ICAM-1 play a key role in the earlyerosclerosis both by inhibiting IL-1 release from macro-
phase of inflammatory reactions in glomerulonephritis.phages and by inhibiting the formation of oxidized LDL,
We demonstrated that probucol inhibited LPS-inducedwhich itself enhances IL-1 release from macrophages
ICAM-1 expression in cultured rat mesangial cells, and[8–10].
that this inhibition was mediated by blocking the releaseIn this context, we proposed that probucol might sup-
of IL-1 activity from these cells. These results throwpress inflammatory processes of glomerulonephritis by
light on the therapeutic application of probucol to theinhibiting IL-1 release from mesangial cells. To deter-
suppression of the inflammatory process of glomerulone-mine whether or not probucol would reduce the IL-1
phritis.secretion from mesangial cells and consequently sup-
press ICAM-1 expression, IL-1 activity in the culture
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